Charlene A. Banard - 01 Mar 2023 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role: EVP, Chief Technical Officer
Signature: /s/ Jeff Kiekhofer, Attorney-in-Fact for Charlene A. Banard
Issuer symbol: ATRA
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2023, 16:16:01 UTC
Previous filing: 16 Dec 2022
Next filing: 18 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRA	Common Stock	Award	$0	+139,700	+90%	$0.000000	295,050	01 Mar 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATRA	Employee Stock Option (Right to Buy)	Award	$0	+314,325		$0.000000	314,325	01 Mar 2023	Common Stock	314,325	$3.91	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted stock units vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2023, subject to the reporting person's continuous service. "Company Quarterly Vesting Date" means March 1, May 15, August 15 and November 15 of each year.
F2	1/36th of the shares subject to the stock option vest and become exercisable each month, with the initial installment vesting on April 1, 2023, subject to the reporting person's continuous service.